PURIFICATION, REFORMULATION AND PHARMACOKINETICS OF NITROSYLCO

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$200,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
N43CO201000107
Agency Tracking Number:
N43CO201000107
Solicitation Year:
2010
Solicitation Topic Code:
NCI
Solicitation Number:
PHS2010-1
Small Business Information
BNOAT ONCOLOGY, INC.
BNOAT ONCOLOGY, INC., 411 WOLF LEDGES PKWY STE 105, AKRON, OH, 44311
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
961695025
Principal Investigator:
Joseph Bauer
() -
Business Contact:
(330) 972-2748
Research Institution:
n/a
Abstract
Oncology remains a major market of unmet need. BNOAT Oncology¿s long-term objective is New Drug Approval of its lead candidate nitrosylcobalamin, a tumor-specific, apoptosis-inducing, anti-cancer drug. Research Design and Methods: Nitrosylcobalamin purification will include crystallizations, various chromatographic techniques including basic ion-exchange resins, neutral ion exchange, gel filtration chromatography, and size exclusion chromatography. Proprietary formulation design algorithms and phospholipid gel (PG) depot formulation templates will be used in the development of the intravenous-depot formulation and the oral formulation. A variety of excipients will be used to design test formulations for their ability to achieve an optimized PK profile and work independently of intrinsic factor and/or vitamin B12 levels in the gut. Anticipated Results: A PG Depot formulation with a duration of release over a time course of 3-7 days in addition to an oral delivery independent of cobalamin metabolism. Purity (98%) of nitrosylcobalamin as determined by HPLC analysis.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government